Hyperkalaemia in CKD and diabetes
The following write up is from the 7th Joint Meeting of ABCD & UKKA 2025 which was held on the 12th February 2025 at the Holiday Inn, Birmingham airport.
DOI:
https://doi.org/10.15277/bjd.2025.481Keywords:
chronic kidney disease, diabetes, heart failure, hyperkalaemia, potassium binders, aldosteroneAbstract
Hyperkalaemia, both acute and chronic, limits the ability to optimally manage people with chronic kidney disease, cardiovascular disease and diabetes with renin angiotensin aldosterone system inhibitors. Data demonstrate the benefits of optimal doses of these drugs in delaying kidney, cardiac and diabetic kidney disease progression and reducing mortality. This review briefly summarises the strategies for hyperkalaemia management and the recommendations from the UK guidelines.
References
Fisch C, Knoebel SB, Feigenbaum H, Greenspan K. Potassium and the monophasic action potential, electrocardiogram, conduction and arrhythmias. Prog Cardiovasc Dis 1966; 8:387–418. https://doi.org/10.1016/s0033-0620(66)80029-4
Welling PA. Regulation of renal potassium secretion; molecular mechanisms. Seminars Nephrol 2013;33:215-28. https://doi.org/10.1016/j.semnephrol.2013.04.002
Rossi GM, Regolisti G, Peyronel F, Fiaccadori E. Recent insights into sodium and potassium handling by the aldosterone-sensitive distal nephron: a review of the relevant physiology. J Nephrol 2020;33:431-45. https://doi.org/10.1007/s40620-019-00684-1
Kamel S, Schreiber, Halperin ML. Renal potassium physiology: integration of renal response to dietary potassium depletion. Kidney Intern 2018;93:41-53. https://doi.org/10.1016/j.kint.2017.08.018
Mathialahan T, Maclennan KA, Sandle LN, et al. Enhanced large intestinal potassium permeability in end-stage renal disease. J Pathol 2005;206:46-51. https://doi.org/10.1002/path.1750
Rossing P, Caramori ML, Chan JCN, et al. Executive summary of the KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease: an update based on rapidly emerging new evidence. Kidney Int 2022;102:990-9. https://doi.org/10.1016/j.kint.2022.06.013
Davies MJ, Aroda VR, Collins BS, Gabbay RA, et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2022; 45:2753–86. https://doi.org/10.2337/dci22-0034
Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. Circulation 2022;145:e895-e1032. https://doi.org/10.1161/CIR.00000000001 063
Basi S, Lewis JB. Microalbuminuria as a target to improve cardiovascular and renal outcomes. Am J Kidney Dis 2006; 47(6):927-46. https://doi.org/10.1053/j.ajkd.2006.02.182. PMID: 16731288.
Epstein M, Reaven NL, Funk SE, McGaughey KJ, Oestreicher N, Knispel J. Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors. Am J Manag Care 2015;21(11 Suppl): S212-20. PMID: 26619183.
Linde C, Bakhai A, Furuland H, et al. Real-world associations of renin-angiotensin-aldosterone system inhibitor dose, hyperkalemia, and adverse clinical outcomes in a cohort of patients with new-onset chronic kidney disease or heart failure in the United Kingdom. J Am Heart Assoc 2019;8(22):e012655. https://doi.org/ 10.1161/JAHA.119.012655.
Bhandari S, Mehta S, Khwaja A, et al; STOP ACEi Trial Investigators. Renin-angiotensin system inhibition in advanced chronic kidney disease. N Engl J Med 2022;387(22):2021-32. https://doi.org/10.1056/NEJMoa2210639. Epub 2022 Nov 3. PMID: 36326117.
Neuen BL, Heerspink HJL, Vart P, et al. Estimated lifetime cardiovascular, kidney, and mortality benefits of combination treatment with SGLT2 inhibitors, GLP-1 receptor agonists, and nonsteroidal MRA compared with conventional care in patients with type 2 diabetes and albuminuria. Circulation 2024;149(6):450-62. https://doi.org/10.1161/CIRCULATIONAHA.123.067584. Epub 2023 Nov 12. PMID: 37952217.
Thomsen RW, Nicolaisen SK, Hasvold P, et al. Elevated potassium levels in patients with chronic kidney disease: occurrence, risk factors and clinical outcomes--a Danish population-based cohort study. Nephrol Dial Transplant 2018;33(9):1610-20. https://doi.org/ 10.1093/ndt/gfx312.
Meng QH, Wagar EA. Pseudohyperkalemia: a new twist on an old phenomenon. Crit Rev Clin Lab Sci 2015;52:45–55. https://doi.org/10.3109/ 10408363.2014.966898
Alfonzo A, Harrison A, Baines R, Chu A, Mann S, MacRury M. Clinical practice guidelines treatment of acute hyperkalaemia in adults. https://www.ukkidney.org/sites/renal.org /files accessed 3d March 2025.
Kosiborod M, Rasmussen HS, Lavin P, et al. Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial. JAMA 2014; 312:2223–33. https://doi.org/10.1001/jama.2014.15688
Weir MR, Bakris GL, Bushinsky DA, et al. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med 2015;372:211–21. https://doi.org/10.1056/NEJMoa1410853
KDIGO 2024. Clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney International 2024;105(Suppl 4S):S117–S314. https://kdigo.org/guidelines/ckd-evaluation-and-management/. Accessed 3rd March 2025.
Palmer BF, Clegg DJ Achieving the benefits of a high potassium, paleolithic diet, without the toxicity. Mayo Clinic Proceedings 2016;91(4):496-508.
Packham DK, Kosiborod M. Potential new agents for the management of hyperkalemia. Am J Cardiovasc Drugs 2016;16:19–31. https://doi.org/10.1007/s40256-015-0130-7
Tamargo J, Caballero R, Delpón E. New therapeutic approaches for the treatment of hyperkalemia in patients treated with renin-angiotensin-aldosterone system inhibitors. Cardiovasc Drugs Ther 2018;32:99–119. https://doi.org/10.1007/s10557-017-6767-5
Pitt B, Bakris GL, Bushinsky DA, et al. Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors. Eur J Heart Fail 2015; 17:1057–65. https://doi.org/10.1002/ejhf.402
Bakris G, Pitt B, Weir M, et al. Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease: the AMETHYST-DN randomized clinical trial. JAMA 2015; 314:151–61. https://doi.org/10.1001/jama.2015.7446
Roger SD, Lavin PT, Lerma EV, et al. Long-term safety and efficacy of sodium zirconium cyclosilicate for hyperkalaemia in patients with mild/moderate versus severe/end-stage chronic kidney disease: comparative results from an open-label, phase 3 study. Nephrol Dial Transplant 2021;36:137–50. https://doi.org/10.1093/ndt/gfz285
Watson KE, Dhaliwal K, McMurtry E, et al. Sick day medication guidance for people with diabetes, kidney disease, or cardiovascular disease: a systematic scoping review. Kidney Med 2022;4(9): 100491. https://doi.org/10.1016/j.xkme.2022.100491. PMID: 36046611; PMCID: PMC9420951
Published
Issue
Section
License
Copyright (c) 2025 British Journal of Diabetes
This work is licensed under a Creative Commons Attribution 4.0 International License.
Manuscripts published in the June 2024 edition and after in the BJD have been published in open access under a Creative Commons Attribution 4.0 International License and available at https://www.bjd-abcd.com. Prior year articles are available free of charge via our website.
